Vaccine Co-Development and Technology Transfer
SK bioscience is conducting various joint development and technology transfer projects with global companies
from material supply to product development, clinical trials, and sales.
Joint development
We provide the best solution for faster development with advanced competitive R&D systems,
manufacturing processes, and investme
and manufacturing processes and future-oriented investments in joint development.
- 2.5 Years
- R&D
- NCS (tox)
- 1 Year
- PhaseⅠ/Ⅱ
- 3 Years
- Facility
establishment - CTM* manufacturing
- Facility
- 2 Years
- Phase Ⅲ
- 1 Year
- BLA
- 2.5 Years
- R&D
- NCS(tox)
- 1 Year
- PhaseⅠ/Ⅱ
-
- Facility
establishment - CTM* manufacturing
- Facility
- 1.5 Years
- Phase Ⅲ
- 0.8 Year
- BLA
from basic research
to commercialization
Joint development process
- Full or partial funding
-
Process development / Preclinical
Small scale
manufacturingR&D CENTER
-
Clinical
Commercial scale
manufacturingL HOUSE
- BLA/WHO PQ
-
Supply
Post marketing
commitment
We are working with various global companies and foundations for global healthcare.
PCV
R&D, production and marketing
for next generation PCV in 2014
TCV
Co-development with IVI
(Bill & Melinda Gates Foundation) in 2013
NRRV
Co-development of non-replicating rotavirus vaccine with Path (Bill & Melinda Gates Foundation) in 2017
COVID 19
(NBP2001)
Development of a recombinant protein vaccine with funding from the Korea Disease Control and Prevention Agency, Ministry of Health and Welfare, and Ministry of Trade, Industry & Energy
COVID 19
(GBP510)
Study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials
Sarbecovirus
Development of a general-purpose vaccine for Sarbecovirus under CEPI supported
Nasal Spray
Co-developement with Bill&Melinda Gates Foundation, IAVI, IPD
